

Stephanie J Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8426241/publications.pdf>

Version: 2024-02-01

295
papers

27,390
citations

8732

75
h-index

6454

157
g-index

295
all docs

295
docs citations

295
times ranked

14277
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term neurocognitive and quality of life outcomes in survivors of pediatric hematopoietic cell transplant. <i>Journal of Cancer Survivorship</i> , 2022, 16, 696-704.	1.5	8
2	Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 34-42.	0.6	13
3	A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. <i>Blood Advances</i> , 2022, 6, 259-269.	2.5	5
4	Adding Centralized Electronic Patient-Reported Outcome Data Collection to an Established International Clinical Outcomes Registry. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 112.e1-112.e9.	0.6	4
5	HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. <i>Blood</i> , 2022, 139, 1452-1468.	0.6	52
6	Number of HLA-Mismatched Eplets Is Not Associated with Major Outcomes in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 107.e1-107.e8.	0.6	5
7	Outcomes after hematopoietic cell transplantation among non-English- compared to English-speaking recipients. <i>Bone Marrow Transplantation</i> , 2022, 57, 440-444.	1.3	3
8	Regenerating islet-derived protein 3-1± is a prognostic biomarker for gastrointestinal chronic graft-versus-host disease. <i>Blood Advances</i> , 2022, 6, 2981-2986.	2.5	8
9	Three US Food and Drug Administration“approved therapies for chronic GVHD. <i>Blood</i> , 2022, 139, 1642-1645.	0.6	30
10	Prospective phase II trial of montelukast to treat bronchiolitis obliterans syndrome after hematopoietic cell transplant and investigation into BOS pathogenesis. <i>Transplantation and Cellular Therapy</i> , 2022, , .	0.6	5
11	External validation of the <scp>HIGH“LOW</scp> model: A predictive score for venous thromboembolism after allogeneic transplant. <i>American Journal of Hematology</i> , 2022, 97, 740-748.	2.0	1
12	Prevalence of and Factors Associated with Marital Distress among Hematopoietic Cell Transplantation Survivors: Results from a Large Cross-Sectional Study. <i>Transplantation and Cellular Therapy</i> , 2022, , .	0.6	0
13	Yin and Yang of Psychological Health in the Cancer Experience: Does Positive Psychology Have a Role?. <i>Journal of Clinical Oncology</i> , 2022, 40, 2402-2407.	0.8	12
14	Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 409.e1-409.e10.	0.6	26
15	A Review of Oral Chronic Graft-Versus-Host Disease: Considerations for dental hygiene practice.. <i>Journal of Dental Hygiene: JDH / American Dental Hygienists' Association</i> , 2022, 96, 6-17.	0.1	0
16	Peer support in patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT): a qualitative study. <i>Bone Marrow Transplantation</i> , 2022, 57, 1277-1286.	1.3	4
17	Long-term patient-reported neurocognitive outcomes in adult survivors of hematopoietic cell transplant. <i>Blood Advances</i> , 2022, 6, 4347-4356.	2.5	3
18	Natural Killer Cell Alloreactivity Predicted By Killer Cell Immunoglobulin-Like Receptor Ligand Mismatch Does Not Impact Engraftment in Umbilical Cord Blood and Haploidentical Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 483.e1-483.e7.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 426-445.	0.6	16
20	Neuropathy and Muscle Cramps in Autologous and Allogeneic Hematopoietic Cell Transplantation Survivors. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 608.e1-608.e9.	0.6	5
21	Genetic testing in severe aplastic anemia is required for optimal hematopoietic cell transplant outcomes. <i>Blood</i> , 2022, 140, 909-921.	0.6	18
22	Correlation of Patient-Reported Outcomes with Clinical Organ Responses: Data from the Belumosudil Chronic Graft-versus-Host Disease Studies. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 700.e1-700.e6.	0.6	4
23	Specific Class I HLA Supertypes but Not HLA Zygosity or Expression Are Associated with Outcomes following HLA-Matched Allogeneic Hematopoietic Cell Transplant: HLA Supertypes Impact Allogeneic HCT Outcomes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 142.e1-142.e11.	0.6	3
24	Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. <i>Cancer</i> , 2021, 127, 609-618.	2.0	12
25	Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 183.e1-183.e7.	0.6	6
26	Prognostic Biomarkers for Thrombotic Microangiopathy after Acute Graft-versus-Host Disease: A Nested Case-Control Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 308.e1-308.e8.	0.6	12
27	Sexual Functioning in Long-Term Survivors of Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 80.e1-80.e12.	0.6	17
28	HIGH-2-LOW risk model to predict venous thromboembolism in allogeneic transplant patients after platelet engraftment. <i>Blood Advances</i> , 2021, 5, 167-175.	2.5	12
29	The Future of Chronic Graft-Versus-Host Disease: Introduction to the 2020 National Institutes of Health Consensus Development Project Reports. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 448-451.	0.6	13
30	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 452-466.	0.6	24
31	Epigenetic Aging and Hematopoietic Cell Transplantation in Patients With Severe Aplastic Anemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 313.e1-313.e8.	0.6	8
32	Sclerotic chronic GVHD: you may WANT to block WNT. <i>Blood</i> , 2021, 137, 2284-2284.	0.6	0
33	A positive psychology intervention to promote health outcomes in hematopoietic stem cell transplantation: the PATH proof-of-concept trial. <i>Bone Marrow Transplantation</i> , 2021, 56, 2276-2279.	1.3	14
34	Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 387-400.	0.6	26
35	Late Kidney Morbidity and Mortality in Hematopoietic Cell Transplant Survivors. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 434.e1-434.e6.	0.6	7
36	Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation. <i>American Journal of Hematology</i> , 2021, 96, 1137-1146.	2.0	8

#	ARTICLE	IF	CITATIONS
37	ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2021, 39, 1888-1898.	0.8	83
38	CMV exposure drives long-term CD57+ CD4 memory T-cell inflation following allogeneic stem cell transplant. <i>Blood</i> , 2021, 138, 2874-2885.	0.6	16
39	Home Spirometry Telemonitoring for Early Detection of Bronchiolitis Obliterans Syndrome in Patients with Chronic Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 616.e1-616.e6.	0.6	20
40	Prognostic impact of pre-transplant chromosomal aberrations in peripheral blood of patients undergoing unrelated donor hematopoietic cell transplant for acute myeloid leukemia. <i>Scientific Reports</i> , 2021, 11, 15004.	1.6	4
41	Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. <i>Blood</i> , 2021, 138, 2278-2289.	0.6	124
42	Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2021, 385, 228-238.	13.9	209
43	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 545-557.	0.6	72
44	Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2397-2409.	0.8	19
45	Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 679.e1-679.e8.	0.6	10
46	Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 926.e1-926.e10.	0.6	2
47	Reply to A. Heine et al. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01559.	0.8	0
48	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 632-641.	0.6	21
49	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 729-737.	0.6	29
50	Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. <i>Blood Advances</i> , 2021, 5, 4549-4559.	2.5	8
51	Relevance of Plasma Matrix Metalloproteinase-9 for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 759.e1-759.e8.	0.6	8
52	Distress in a Pandemic - The Association of the Coronavirus Disease-2019 (COVID-19) Pandemic with Distress and Quality of Life in Hematopoietic Stem Cell Transplantation (HSCT). <i>Transplantation and Cellular Therapy</i> , 2021, , .	0.6	8
53	Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. <i>Blood Advances</i> , 2021, 5, 4278-4284.	2.5	36
54	Thrombotic Microangiopathy Increases the Risk of Chronic Kidney Disease but Not Overall Mortality in Long-term Transplant Survivors. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 864.e1-864.e5.	0.6	1

#	ARTICLE	IF	CITATIONS
55	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 817-835.	0.6	62
56	Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients post-“unrelated HCT. <i>Blood Advances</i> , 2021, 5, 66-70.	2.5	6
57	Whole Exome Sequencing in Severe Aplastic Anemia Identifies Unrecognized Inherited Subset with Inferior Survival after Hematopoietic Cell Transplant. <i>Blood</i> , 2021, 138, 605-605.	0.6	0
58	Rare Variant Genetic Association Study for Transplant-Associated Thrombotic Microangiopathy (TA-TMA) Via Whole Exome Sequencing. <i>Blood</i> , 2021, 138, 745-745.	0.6	1
59	Carfilzomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Pilot Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 278-284.	2.0	10
60	Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation. <i>JAMA Oncology</i> , 2020, 6, e192974.	3.4	15
61	Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 34-43.	2.0	93
62	Survivorship after Autologous Hematopoietic Cell Transplantation for Lymphoma and Multiple Myeloma: Late Effects and Quality of Life. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 407-412.	2.0	16
63	Pre-transplant short telomeres are associated with high mortality risk after unrelated donor haematopoietic cell transplant for severe aplastic anaemia. <i>British Journal of Haematology</i> , 2020, 188, 309-316.	1.2	9
64	Time-to-event analysis when the event is defined on a finite time interval. <i>Statistical Methods in Medical Research</i> , 2020, 29, 1573-1591.	0.7	5
65	Disability Related to Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 772-777.	2.0	16
66	Early Post-Transplantation Spirometry Is Associated with the Development of Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 943-948.	2.0	19
67	Reliability and Validity of the Modified 7-Day Lee Chronic Graft-versus-Host Disease Symptom Scale. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 562-567.	2.0	16
68	Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults. <i>Bone Marrow Transplantation</i> , 2020, 55, 906-917.	1.3	33
69	Who Enrolls in an Online Cancer Survivorship Program? Reach of the INSPIRE Randomized Controlled Trial for Hematopoietic Cell Transplantation Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1948-1954.	2.0	6
70	Decisional involvement and information preferences of patients with hematologic malignancies. <i>Blood Advances</i> , 2020, 4, 5492-5500.	2.5	8
71	Association of donor IFNL4 genotype and non-relapse mortality after unrelated donor myeloablative haematopoietic stem-cell transplantation for acute leukaemia: a retrospective cohort study. <i>Lancet Haematology</i> , 2020, 7, e715-e723.	2.2	8
72	Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020, 4, 2409-2417.	2.5	14

#	ARTICLE	IF	CITATIONS
73	Gender differences in question-asking at the 2019 American Society of Hematology Annual Meeting. <i>Blood Advances</i> , 2020, 4, 5473-5479.	2.5	7
74	Return-to-Work Guidelines and Programs for Post-Hematopoietic Cell Transplantation Survivors: An Initial Survey. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1520-1526.	2.0	7
75	Reply to J. Schildmann et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 2815-2816.	0.8	1
76	Estimation and inference for semi-competing risks based on data from a nested case-control study. <i>Statistical Methods in Medical Research</i> , 2020, 29, 3326-3339.	0.7	2
77	Age and gender differences in financial distress among hematopoietic cell transplant survivors. <i>Supportive Care in Cancer</i> , 2020, 28, 4361-4371.	1.0	15
78	Improving Quality of Life in Hematopoietic Stem Cell Transplantation Survivors Through a Positive Psychology Intervention. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1144-1153.	2.0	11
79	Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Haematology</i> . 2020, 7, e100-e111.	2.2	59
80	Population Frequency of Fanconi Pathway Gene Variants and Their Association with Survival After Hematopoietic Cell Transplantation for Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 817-822.	2.0	6
81	Genome-wide Association Study Identifies HLA-DPB1 as a Significant Risk Factor for Severe Aplastic Anemia. <i>American Journal of Human Genetics</i> , 2020, 106, 264-271.	2.6	25
82	Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia. <i>Blood Advances</i> , 2020, 4, 40-46.	2.5	11
83	Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia. <i>Blood Advances</i> , 2020, 4, 1350-1356.	2.5	19
84	Late infectious complications in hematopoietic cell transplantation survivors: a population-based study. <i>Blood Advances</i> , 2020, 4, 1232-1241.	2.5	16
85	Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e177-e182.	2.0	378
86	Ixazomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1612-1619.	2.0	12
87	Current Practices for Screening and Management of Financial Distress at NCCN Member Institutions. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 825-831.	2.3	34
88	Pre-Transplant Clonal Mosaicism Is Associated with Increased Relapse and Lower Survival in Acute Lymphoblastic Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplant. <i>Blood</i> , 2020, 136, 9-10.	0.6	0
89	Towards Identifying the Target of Autoimmunity in Aplastic Anemia. <i>Blood</i> , 2020, 136, 2-2.	0.6	0
90	Improving Donor Selection for Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide through Selective HLA-Mis/Matching. <i>Blood</i> , 2020, 136, 24-26.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Rates and Risk Factors for Post-Traumatic Stress Disorder Symptomatology among Adult Hematopoietic Cell Transplant Recipients and Their Informal Caregivers. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 145-150.	2.0	28
92	The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2468-2473.	2.0	4
93	Comprehensive viromewide antibody responses by systematic epitope scanning after hematopoietic cell transplantation. <i>Blood</i> , 2019, 134, 503-514.	0.6	9
94	Donor HLA-E Status Associates with Disease-Free Survival and Transplant-Related Mortality after Non In Vivo T Cell-Depleted HSCT for Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2357-2365.	2.0	9
95	Organ Changes Associated with Provider-Assessed Responses in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1869-1874.	2.0	1
96	Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients. <i>Blood Advances</i> , 2019, 3, 2764-2777.	2.5	12
97	Kinetics of immune cell reconstitution predict survival in allogeneic bone marrow and G-CSFâ€mobilized stem cell transplantation. <i>Blood Advances</i> , 2019, 3, 2250-2263.	2.5	37
98	Multiple functional variants in the IL1RL1 region are pretransplant markers for risk of GVHD and infection deaths. <i>Blood Advances</i> , 2019, 3, 2512-2524.	2.5	7
99	Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 451-458.	2.0	19
100	Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 570-576.	2.0	51
101	Positive Psychological Constructs and Health Outcomes in Hematopoietic Stem Cell Transplantation Patients: A Systematic Review. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e5-e16.	2.0	34
102	Machine learning reveals chronic graft-versus-host disease phenotypes and stratifies survival after stem cell transplant for hematologic malignancies. <i>Haematologica</i> , 2019, 104, 189-196.	1.7	44
103	Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 599-605.	2.0	20
104	The effect of NIMA matching in adult unrelated mismatched hematopoietic stem cell transplantation â€a joint study of the Acute Leukemia Working Party of the EBMT and the CIBMTR. <i>Bone Marrow Transplantation</i> , 2019, 54, 849-857.	1.3	2
105	KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) - Long-Term Follow-up of a Phase 2a Study (KD025-208). <i>Blood</i> , 2019, 134, 872-872.	0.6	7
106	Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1049-1056.	2.0	98
107	Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1727-1732.	2.0	8
108	Donor telomere length and causes of death after unrelated hematopoietic cell transplantation in patients with marrow failure. <i>Blood</i> , 2018, 131, 2393-2398.	0.6	15

#	ARTICLE	IF	CITATIONS
109	Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. <i>Bone Marrow Transplantation</i> , 2018, 53, 449-456.	1.3	92
110	Evaluation of a Machine Learning-Based Prognostic Model for Unrelated Hematopoietic Cell Transplantation Donor Selection. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1299-1306.	2.0	16
111	Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients. <i>Blood</i> , 2018, 131, 1743-1754.	0.6	21
112	No association between donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia. <i>Bone Marrow Transplantation</i> , 2018, 53, 383-391.	1.3	13
113	ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1119-1124.	2.0	33
114	Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1920-1927.	2.0	40
115	Severity, course, and predictors of sleep disruption following hematopoietic cell transplantation: a secondary data analysis from the BMT CTN 0902 trial. <i>Bone Marrow Transplantation</i> , 2018, 53, 1038-1043.	1.3	6
116	Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 393-399.	2.0	24
117	Patient-reported outcomes in acute myeloid leukemia: Where are we now?. <i>Blood Reviews</i> , 2018, 32, 81-87.	2.8	41
118	Quality of life from the perspective of the patient with acute myeloid leukemia. <i>Cancer</i> , 2018, 124, 145-152.	2.0	32
119	PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. <i>Cancer</i> , 2018, 124, 841-849.	2.0	38
120	Impact of HLA Alleles on Outcomes of Allogeneic Transplantation for B Cell Non-Hodgkin Lymphomas: A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 827-831.	2.0	1
121	Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 555-562.	2.0	50
122	Telomere Length Calibration from qPCR Measurement: Limitations of Current Method. <i>Cells</i> , 2018, 7, 183.	1.8	23
123	In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance. <i>Blood Advances</i> , 2018, 2, 1773-1783.	2.5	23
124	A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801. <i>Haematologica</i> , 2018, 103, 1915-1924.	1.7	34
125	Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2271-2276.	2.0	31
126	Impact of Psychological Distress on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2285-2292.	2.0	38

#	ARTICLE	IF	CITATIONS
127	Intensity of End-of-Life Care for Patients with Hematologic Malignancies and the Role of Race/Ethnicity. <i>Journal of Palliative Medicine</i> , 2018, 21, 1466-1471.	0.6	26
128	Patient-reported outcomes and health status associated with chronic graft-versus-host disease. <i>Haematologica</i> , 2018, 103, 1535-1541.	1.7	56
129	EBMT~NIH~CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. <i>Bone Marrow Transplantation</i> , 2018, 53, 1401-1415.	1.3	243
130	Chromosomal Aberrations and Survival after Unrelated Donor Hematopoietic Stem Cell Transplant in Patients with Fanconi Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2003-2008.	2.0	9
131	Prediction of absolute risk of acute graft-versus-host disease following hematopoietic cell transplantation. <i>PLoS ONE</i> , 2018, 13, e0190610.	1.1	20
132	Risk Score for the Development of Veno-Occlusive Disease after Allogeneic Hematopoietic Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2072-2080.	2.0	50
133	KD025-208: A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) ~ Pharmacodynamics and Updated Results. <i>Blood</i> , 2018, 132, 602-602.	0.6	6
134	Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. <i>Cancer</i> , 2017, 123, 1828-1838.	2.0	73
135	Late effects of blood and marrow transplantation. <i>Haematologica</i> , 2017, 102, 614-625.	1.7	126
136	Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2017, 376, 536-547.	13.9	586
137	An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2017, 130, 360-367.	0.6	52
138	Association of Plasma CD163 Concentration with De Novo~Onset Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1250-1256.	2.0	38
139	Cancer and treatment distress psychometric evaluation over time: A BMT CTN 0902 secondary analysis. <i>Cancer</i> , 2017, 123, 1416-1423.	2.0	28
140	Current Use and Trends in Hematopoietic Cell Transplantation in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1417-1421.	2.0	205
141	Stratification of Allogeneic Hematopoietic Cell Transplant Patients by Risk of Developing Veno-Occlusive Disease: A Model for Assigning a Risk Score. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S302-S303.	2.0	2
142	Investigating the Association of Genetic Admixture and Donor/Recipient Genetic Disparity with Transplant Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1029-1037.	2.0	10
143	Classification systems for chronic graft-versus-host disease. <i>Blood</i> , 2017, 129, 30-37.	0.6	218
144	Racial and ethnic disparities in hematologic malignancies. <i>Blood</i> , 2017, 130, 1699-1705.	0.6	111

#	ARTICLE	IF	CITATIONS
145	Radiation toxicity in patients with collagen vascular disease and intrathoracic malignancy treated with modern radiation techniques. <i>Radiotherapy and Oncology</i> , 2017, 125, 301-309.	0.3	11
146	Pretransplantation Exercise and Hematopoietic Cell Transplantation Survival: A Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0902). <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 161-164.	2.0	10
147	Inter-observer and inter-scan tumour volume delineation variability on cone beam computed tomography in patients treated with stereotactic body radiation therapy for early-stage non-small cell lung cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017, 61, 93-98.	0.9	3
148	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Patient-Centered Outcomes Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 538-551.	2.0	112
149	Morbidity and Mortality Differences Between Hematopoietic Cell Transplantation Survivors and Other Cancer Survivors. <i>Journal of Clinical Oncology</i> , 2017, 35, 306-313.	0.8	47
150	Replication of associations between genetic polymorphisms and chronic graft-versus-host disease. <i>Blood</i> , 2016, 128, 2450-2456.	0.6	32
151	Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. <i>Blood</i> , 2016, 128, 2350-2358.	0.6	43
152	Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 752-758.	2.0	21
153	Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1410-1415.	2.0	22
154	Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease. <i>Blood</i> , 2016, 127, 160-166.	0.6	43
155	Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2256-2263.	2.0	20
156	Trajectories of Quality of Life after Hematopoietic Cell Transplantation: Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network 0902 Data. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2077-2083.	2.0	14
157	Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT) Tj ETQq1 1 0.784314rgBT /0	2.0	57
158	Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation. <i>JAMA Oncology</i> , 2016, 2, 1583.	3.4	110
159	Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1932-1939.	1.5	67
160	Effect of Recipient Age and Stem Cell Source on the Association between Donor Telomere Length and Survival after Allogeneic Unrelated Hematopoietic Cell Transplantation for Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2276-2282.	2.0	22
161	Genetic risk factors for sclerotic graft-versus-host disease. <i>Blood</i> , 2016, 128, 1516-1524.	0.6	18
162	Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells. <i>Blood</i> , 2016, 127, 3082-3091.	0.6	83

#	ARTICLE	IF	CITATIONS
163	Biomarker Panel for Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2016, 34, 2583-2590.	0.8	118
164	Validation Study Failed to Confirm an Association between Genetic Variants in the Base Excision Repair Pathway and Transplant-Related Mortality and Relapse after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1531-1532.	2.0	6
165	Translation, Cross-Cultural Adaptation, and Validation of the Lee Chronic Graft-versus-Host Disease Symptom Scale in a Brazilian Population. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1313-1318.	2.0	3
166	Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 449-455.	2.0	113
167	Pretransplantation Supportive and Palliative Care Consultation for High-Risk Hematopoietic Cell Transplantation Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1299-1305.	2.0	57
168	Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. <i>Lancet Oncology</i> , The, 2016, 17, 164-173.	5.1	283
169	Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 710-716.	2.0	151
170	A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. <i>Clinical Cancer Research</i> , 2016, 22, 319-327.	3.2	68
171	National Survey of Hematopoietic Cell Transplantation Center Personnel, Infrastructure, and Models of Care Delivery. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1308-1314.	2.0	45
172	Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease. <i>Haematologica</i> , 2015, 100, 690-695.	1.7	29
173	2014 National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: Preface to the Series. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 387-388.	2.0	51
174	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 780-792.	2.0	124
175	NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. The 2014 Pathology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 589-603.	2.0	228
176	Bone Marrow or Peripheral Blood for Reduced-Intensity Conditioning Unrelated Donor Transplantation. <i>Journal of Clinical Oncology</i> , 2015, 33, 364-369.	0.8	51
177	Association Between Donor Leukocyte Telomere Length and Survival After Unrelated Allogeneic Hematopoietic Cell Transplantation for Severe Aplastic Anemia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 594.	3.8	73
178	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 984-999.	2.0	293
179	Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1589-1596.	2.0	37
180	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1167-1187.	2.0	182

#	ARTICLE	IF	CITATIONS
181	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1343-1359.	2.0	105
182	Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 266-274.	2.0	331
183	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 389-401.e1.	2.0	2,636
184	Toll-Like Receptor Polymorphisms in Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 259-265.	2.0	11
185	Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 2020-2028.	3.2	98
186	The Impact of Pre-Transplant Depression on Outcomes of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 265-265.	0.6	3
187	A Predictive Model Using Telomere Length to Select Optimal Donors for Hematopoietic Stem Cell Transplant (HCT) for Acute Leukemia. <i>Blood</i> , 2015, 126, 398-398.	0.6	1
188	Evaluation of the Impact of Non-Inherited Maternal Antigens on the Outcome of HLA Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation for Hematological Malignancies on Behalf of the ALWP of the EBMT and the CIBMTR. <i>Blood</i> , 2015, 126, 3226-3226.	0.6	0
189	Anterior segment optical coherence tomography evaluation of ocular graft-versus-host disease: a case study. <i>Quantitative Imaging in Medicine and Surgery</i> , 2015, 5, 163-70.	1.1	6
190	Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. <i>Haematologica</i> , 2014, 99, 1618-1623.	1.7	29
191	Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. <i>Blood</i> , 2014, 124, 1363-1371.	0.6	86
192	Assessment of Joint and Fascia Manifestations in Chronic Graft-versus-Host Disease. <i>Arthritis and Rheumatology</i> , 2014, 66, 1044-1052.	2.9	50
193	Survival Improvements in Adolescents and Young Adults after Myeloablative Allogeneic Transplantation for Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 829-836.	2.0	43
194	Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes In Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 337-344.	2.0	76
195	Impact of Age on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1341-1348.	2.0	52
196	Peripheral Blood Hematopoietic Stem Cells for Transplantation of Hematological Diseases from Related, Haploidentical Donors after Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 890-895.	2.0	126
197	Costs of Allogeneic Hematopoietic Cell Transplantation Using Reduced Intensity Conditioning Regimens. <i>Oncologist</i> , 2014, 19, 639-644.	1.9	36
198	Late Cardiovascular Complications after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 794-800.	2.0	84

#	ARTICLE	IF	CITATIONS
199	Exercise and Stress Management Training Prior to Hematopoietic Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1530-1536.	2.0	78
200	Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. <i>Blood</i> , 2014, 123, 786-793.	0.6	94
201	Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2014, 124, 2596-2606.	0.6	228
202	Increased BCR responsiveness in B cells from patients with chronic GVHD. <i>Blood</i> , 2014, 123, 2108-2115.	0.6	86
203	Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. <i>Blood</i> , 2014, 124, 287-295.	0.6	83
204	Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. <i>Blood</i> , 2014, 124, 3221-3227.	0.6	92
205	Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005: Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1116-1123.	2.0	104
206	Interim Analysis of a Phase II Trial of Montelukast for the Treatment of Bronchiolitis Obliterans Syndrome After HSCT Reveals Immunobiology of Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S143.	2.0	6
207	Prevalence of Hematopoietic Cell Transplant Survivors in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1498-1501.	2.0	210
208	Analysis of Gastrointestinal and Hepatic Chronic Graft-versus-Host Disease Manifestations on Major Outcomes: A Chronic Graft-versus-Host Disease Consortium Study. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 784-791.	2.0	43
209	Hand Grip Strength and 2-Minute Walk Test in Chronic Graft-versus-Host Disease Assessment: Analysis from the Chronic GVHD Consortium. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 967-972.	2.0	34
210	Significant Improvement in Survival After Allogeneic Hematopoietic Cell Transplantation During a Period of Significantly Increased Use, Older Recipient Age, and Use of Unrelated Donors. <i>Journal of Clinical Oncology</i> , 2013, 31, 2437-2449.	0.8	223
211	Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. <i>Blood</i> , 2013, 121, 5098-5103.	0.6	93
212	Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. <i>Blood</i> , 2013, 121, 2340-2346.	0.6	55
213	Nonmalignant Late Effects and Compromised Functional Status in Survivors of Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 71-77.	0.8	104
214	Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors. <i>New England Journal of Medicine</i> , 2012, 367, 1487-1496.	13.9	762
215	Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. <i>Haematologica</i> , 2012, 97, 451-458.	1.7	77
216	A disease risk index for patients undergoing allogeneic stem cell transplantation. <i>Blood</i> , 2012, 120, 905-913.	0.6	310

#	ARTICLE	IF	CITATIONS
217	Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. <i>Blood</i> , 2012, 120, 2545-2552.	0.6	101
218	Validation of Measurement Scales in Ocular Graft-versus-Host Disease. <i>Ophthalmology</i> , 2012, 119, 487-493.	2.5	83
219	Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 861-873.	2.0	53
220	Recommended Screening and Preventive Practices for Long-Term Survivors after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 348-371.	2.0	324
221	Clinical Benefit of Response in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1517-1524.	2.0	47
222	Information giving and receiving in hematological malignancy consultations. <i>Psycho-Oncology</i> , 2012, 21, 297-306.	1.0	38
223	Risk factors for acute GVHD and survival after hematopoietic cell transplantation. <i>Blood</i> , 2012, 119, 296-307.	0.6	559
224	Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 124-132.	2.0	26
225	Variation in Management of Immune Suppression after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1528-1536.	2.0	30
226	A Multicenter Pilot Evaluation of the National Institutes of Health Chronic Graft-versus-Host Disease (cGVHD) Therapeutic Response Measures: Feasibility, Interrater Reliability, and Minimum Detectable Change. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1619-1629.	2.0	61
227	Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. <i>Blood</i> , 2011, 117, 4651-4657.	0.6	319
228	Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. <i>Blood</i> , 2011, 117, 6714-6720.	0.6	128
229	Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. <i>Blood</i> , 2011, 117, 3214-3219.	0.6	544
230	Treatment of chronic graft-versus-host disease: Past, present and future. <i>The Korean Journal of Hematology</i> , 2011, 46, 153.	0.7	74
231	Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2011, 118, 456-463.	0.6	75
232	Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium. <i>Haematologica</i> , 2011, 96, 1528-1535.	1.7	48
233	Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. <i>Blood</i> , 2011, 118, 4242-4249.	0.6	196
234	Coping styles, health status and advance care planning in patients with hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2011, 52, 2342-2348.	0.6	21

#	ARTICLE	IF	CITATIONS
235	Access to hematopoietic stem cell transplantation. <i>Cancer</i> , 2010, 116, 3469-3476.	2.0	124
236	Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2010, 28, 1011-1016.	0.8	321
237	Have we made progress in the management of chronic graft-vs-host disease?. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 529-535.	0.7	28
238	Outcomes of Hematologic Malignancies after Unrelated Donor Hematopoietic Cell Transplantation According to Place of Residence. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 368-375.	2.0	26
239	Race and Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 395-402.	2.0	55
240	Validation of the Human Activity Profile Questionnaire in Patients after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1707-1717.	2.0	57
241	Patients' reflections on communication in the second-opinion hematology oncology consultation. <i>Patient Education and Counseling</i> , 2009, 76, 44-50.	1.0	43
242	Race and Socioeconomic Status Influence Outcomes of Unrelated Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1543-1554.	2.0	135
243	Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2009, 113, 5074-5082.	0.6	143
244	Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. <i>Blood</i> , 2009, 114, 702-708.	0.6	218
245	Classification of HLA-Matching for Retrospective Analysis of Unrelated Donor Transplantation: Revised Definitions to Predict Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 748-758.	2.0	186
246	Variation in Supportive Care Practices in Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1231-1238.	2.0	51
247	Treatment Change as a Predictor of Outcome among Patients with Classic Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1380-1384.	2.0	49
248	Recognizing and Managing Chronic Graft-Versus-Host Disease. <i>Hematology American Society of Hematology Education Program</i> , 2008, 2008, 134-141.	0.9	191
249	Individual Physician Practice Variation in Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2008, 26, 2162-2170.	0.8	52
250	High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. <i>Blood</i> , 2007, 110, 4576-4583.	0.6	1,105
251	Histopathologic Diagnosis of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 31-47.	2.0	427
252	Toward Biomarkers for Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. Biomarker Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 126-137.	2.0	139

#	ARTICLE	IF	CITATIONS
253	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 252-266.	2.0	445
254	Ancillary Therapy and Supportive Care of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. Ancillary Therapy and Supportive Care Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 375-396.	2.0	316
255	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 491-505.	2.0	165
256	Costs of Complications after Allogeneic Myeloablative Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 2977-2977.	0.6	0
257	Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States. <i>Blood</i> , 2005, 105, 2979-2987.	0.6	78
258	New approaches for preventing and treating chronic graft-versus-host disease. <i>Blood</i> , 2005, 105, 4200-4206.	0.6	129
259	Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. <i>Blood</i> , 2005, 106, 2903-2911.	0.6	430
260	Sirolimus and Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 551-557.	2.0	153
261	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 945-956.	2.0	3,213
262	X-Linked Clonality Analysis and Quantitative JAK2V617F Assessment Reveals a Strong Association between Clonality and JAK2V617F in PV but Not in ET/MMM, and Identifies a Subset of JAK2V617F Negative ET and MMM Patients with Clonal Hematopoiesis.. <i>Blood</i> , 2005, 106, 117-117.	0.6	2
263	HLA-C Mismatch Is Associated with Inferior Outcome after Unrelated Donor Non-Myeloablative Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 835-835.	0.6	3
264	Sirolimus and Tacrolimus without Methotrexate as Graft-vs.-Host Disease Prophylaxis after Matched, Unrelated Peripheral Blood Stem Cell Transplantation: Excellent GVHD Control with Low Transplant-Related Morbidity and Mortality.. <i>Blood</i> , 2005, 106, 2051-2051.	0.6	0
265	JAK2 V617F Mutation in Essential Thrombocythemia: Clinical Associations and Long-Term Prognostic Relevance.. <i>Blood</i> , 2005, 106, 254-254.	0.6	9
266	The Clinical and PRV-1 Expression Phenotype of Wild-Type, Heterozygous, and Homozygous JAK2 V617F in Polycythemia Vera.. <i>Blood</i> , 2005, 106, 255-255.	0.6	1
267	Comparison of Methotrexate- Versus Sirolimus- Containing Graft-Versus-Host Disease Prophylaxis Regimens after Myeloablative Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 1797-1797.	0.6	0
268	Characterization of Distinct Molecular Signatures in Myeloproliferative Diseases with the JAK2V617F Mutation and Wild Type JAK2.. <i>Blood</i> , 2005, 106, 119-119.	0.6	0
269	Patient-Reported Outcomes in Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2004, 2, 379-383.	2.3	4
270	Physicians' attitudes about quality-of-life issues in hematopoietic stem cell transplantation. <i>Blood</i> , 2004, 104, 2194-2200.	0.6	84

#	ARTICLE	IF	CITATIONS
271	Sirolimus and Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation.. Blood, 2004, 104, 1834-1834.	0.6	2
272	Rituximab Therapy for Steroid-Refractory Chronic GVHD: Safety and Efficacy Analysis.. Blood, 2004, 104, 2251-2251.	0.6	2
273	Patient-Physician Communication about Hematologic Malignancies.. Blood, 2004, 104, 230-230.	0.6	4
274	Oral Mucositis Incidence and Severity after Methotrexate and Non-Methotrexate Containing GVHD Prophylaxis Regimens.. Blood, 2004, 104, 351-351.	0.6	3
275	Family Cord Blood Banking: Experience and Views of Pediatric Hematopoietic Stem Cell Transplant Physicians.. Blood, 2004, 104, 3323-3323.	0.6	0
276	Baseline Physical and Mental Functioning Are Strong Predictors of Post-Stem Cell Transplant Function and Quality of Life.. Blood, 2004, 104, 3322-3322.	0.6	0
277	Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.. Blood, 2004, 104, 1227-1227.	0.6	0
278	High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS.. Blood, 2004, 104, 185-185.	0.6	0
279	Allogeneic B Cell Response to H-Y Minor Histocompatibility Antigens after Donor Lymphocyte Infusion Correlates with Disease Response.. Blood, 2004, 104, 296-296.	0.6	0
280	Similar Outcome of Non-Myeloablative and Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients Greater Than Fifty Years of Age.. Blood, 2004, 104, 300-300.	0.6	2
281	Creating a National Cohort of Myeloproliferative Disorders Using the Internet: A Feasibility Study.. Blood, 2004, 104, 270-270.	0.6	16
282	Prevention of Acute GVHD with Sirolimus Does Not Abrogate the Risk of Chronic GVHD.. Blood, 2004, 104, 3317-3317.	0.6	0
283	Chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation, 2003, 9, 215-233.	2.0	801
284	Optimistic expectations and survival after hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 2003, 9, 389-396.	2.0	57
285	Trends in Survival Rates After Allogeneic Hematopoietic Stem-Cell Transplantation for Acute and Chronic Leukemia by Ethnicity in the United States and Canada. Journal of Clinical Oncology, 2003, 21, 3754-3760.	0.8	77
286	Association of Depressive Syndrome and Early Deaths Among Patients After Stem-Cell Transplantation for Malignant Diseases. Journal of Clinical Oncology, 2002, 20, 2118-2126.	0.8	196
287	Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood, 2002, 100, 406-414.	0.6	503
288	Comparison of T-cellâ€“depleted and nonâ€“T-cellâ€“depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. Blood, 2002, 100, 2697-2702.	0.6	39

#	ARTICLE	IF	CITATIONS
289	A survey of diagnosis, management, and grading of chronic GVHD. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 32-39.	2.0	78
290	Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 444-452.	2.0	211
291	Recovery After Stem-Cell Transplantation for Hematologic Diseases. <i>Journal of Clinical Oncology</i> , 2001, 19, 242-252.	0.8	130
292	Predicting Costs of Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2000, 18, 64-64.	0.8	96
293	Comparative Outcomes of T-Cellâ€Depleted and Nonâ€T-Cellâ€Depleted Allogeneic Bone Marrow Transplantation for Chronic Myelogenous Leukemia: Impact of Donor Lymphocyte Infusion. <i>Journal of Clinical Oncology</i> , 1999, 17, 561-561.	0.8	108
294	Efficacy and Costs of Granulocyte Colony-Stimulating Factor in Allogeneic T-Cell Depleted Bone Marrow Transplantation. <i>Blood</i> , 1998, 92, 2725-2729.	0.6	29
295	A core group of structurally similar HLA-DPB1 alleles drives permissiveness after hematopoietic cell transplantation. <i>Blood</i> , 0, , .	0.6	9